结肠癌是世界上致命的疾病之一，每年约有700,000人死亡（Abdulzehra等人。,2023年[1]）。如今,由于现有治疗结肠癌的方法如放疗和化疗的副作用，靶向纳米载体在癌症治疗中的应用受到广泛关注,其中,尤其是脂质体已经被研究了很多。基于此,隐藏在靶向活性脂质体中的抗肿瘤药物可以选择性地作用于癌细胞。在这次系统审查中，使用各种配体，如叶酸，转铁蛋白,适体,已经综述了透明质酸和cRGD用于脂质体的主动靶向以实现改善的药物向结肠癌细胞的递送。在ScienceDirect的数据库中以英文发表的原始文章，对2012年至2022年的PubMed和Google学者进行了回顾。在发表的26,256篇文章中，19项研究符合纳入标准。体外和体内研究的结果表明，与游离药物和非靶向脂质体相比，靶向脂质体可提高抗癌剂对结肠癌细胞的功效，并减少副作用。据我们所知,这是首次系统综述，显示了使用靶向脂质体改善结肠癌治疗的有希望的结果。
Colon cancer is one of the lethal diseases in the world with approximately 700,000 fatalities annually. Nowadays, due to the side effects of existing methods in the treatment of colon cancer such as radiotherapy and chemotherapy, the use of targeted nanocarriers in cancer treatment has received wide attention, and among them, especially liposomes have been studied a lot. Based on this, anti-tumor drugs hidden in targeted active liposomes can selectively act on cancer cells. In this systematic
review, the use of various ligands such as folic acid, transferrin, aptamer, hyaluronic acid and
cRGD for active targeting of liposomes to achieve improved drug delivery to colon cancer cells has been reviewed. The original articles published in English in the databases of Science Direct, PubMed and Google scholar from 2012 to 2022 were reviewed. From the total of 26,256 published articles, 19 studies met the inclusion criteria. The results of in vitro and in vivo studies have revealed that targeted liposomes lead to increasing the efficacy of anti-cancer agents on colon cancer cells with reducing side effects compared to free drugs and non-targeted liposomes. To the best of our knowledge, this is the first systematic
review showing promising results for improvement treatment of colon cancer using targeted liposomes.
